Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161389 | 0.95 | DPP4 (0.37) | DPP4CES2CES1EPHX1DPP7 | |
| SCHEMBL4167994 | 0.90 | DPP4 (0.35) | DPP4DPP7DPP8GRM2DPP9 | |
| SCHEMBL12856008 | 0.88 | DPP4 (0.48) | DPP4EPHX1DPP7DPP8KCNH2 | |
| SCHEMBL16716340 | 0.88 | DPP4 (0.48) | DPP4EPHX1DPP7DPP8KCNH2 | |
| SCHEMBL28077543 | 0.75 | CES2 (0.43) | DPP4CES2CES1EPHX1GRM2 | |
| SCHEMBL17599037 | 0.73 | CES2 (0.42) | DPP4CES2CES1EPHX1DPP7 | |
| SCHEMBL9318901 | 0.72 | PLG (0.67) | — | |
| SCHEMBL21445109 | 0.71 | CES2 (0.46) | DPP4CES2CES1EPHX1DPP7 | |
| SCHEMBL22507708 | 0.71 | CES2 (0.46) | DPP4CES2CES1EPHX1DPP7 | |
| SCHEMBL6312834 | 0.71 | CES2 (0.46) | DPP4CES2CES1EPHX1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-7423172-B2 | Tyrosine derivatives as PPAR-γ-modulators | LABORATORIOS SALVAT, S.A. (ES) | 2008-09-09 | — | — | US | disclosed |
| US-20070276043-A1 | Tyrosine Derivatives As Ppar-Gamma-Modulators | LABORATORIES SALVAT, S.A. (ES) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | DPP4 2321/4885CES2 1150/4885CES1 667/4885 |
| US-20070276043-A1 | Tyrosine Derivatives As Ppar-Gamma-Modulators | PPARG, PPARD, PPARA | DPP4 2441/4885CES2 1254/4885CES1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.